Quick Answer
Abivax S.A. reported R&D Expense of $177.76 million for fiscal year 2025.
Abivax S.A. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $177.76M | +21.3% |
| 2024 | $146.53M | +42.0% |
| 2023 | $103.18M | +113.6% |
| 2022 | $48.30M | +1.1% |
| 2021 | $47.78M | — |
- Abivax S.A. showed an increase of +21.3% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Abivax S.A.’s r&d expense has grown by 272.0% (from $47.78 million to $177.76 million).
- The most recent figure is from Abivax S.A.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: